| INTRODUCTION
Patients with haemophilia A (HA) are deficient in coagulation factor VIII (FVIII), predisposing them to recurrent bleeds, particularly into joints and muscles, culminating in debilitating arthropathy and long-term morbidity.
1,2 Administration of FVIII, either plasma-derived or recombinant (pd-FVIII or rFVIII), restores clotting capacity and limits uncontrolled bleeding.
Administered prophylactically or on demand, FVIII has been shown to be effective and well tolerated. However, development of FVIII inhibitors remains a serious complication in replacement therapy with major adverse implications on bleeding rates, morbidity, mortality, quality of life and treatment costs. 3 Reduction in the overall immunogenic challenge of replacement factor therapy remains one of the main unmet needs in HA.
Previously untreated patients (PUPs) with HA are at greatest risk of inhibitor development. Approximately 35% develop inhibitors, of which up to 70% are high-titre inhibitors (≥5 Bethesda Unit (BU)/mL). [4] [5] [6] Inhibitors in PUPs with severe HA usually occur within the first 50 exposure days (EDs), with a median around 10-15 EDs. 4, 7 Data from the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study showed cumulative inhibitor incidence of 26.8% in PUPs treated with pdFVIII-containing von Willebrand factor (VWF) and 44.5% in those treated with rFVIIIs derived from hamster cell lines; the majority (90%) of inhibitors developed within the first 20 EDs. 6 FVIII inhibitor development is considered to be a multifactorial event. Patient-related risk factors include the type of F8 gene mutation, age at first exposure, ethnicity and a family history of inhibitors. 5, [8] [9] [10] [11] The type of treatment approach (prophylactic or on demand after 20 EDs), intensity of FVIII exposure (eg during surgery), type of FVIII product (plasma-derived or different generations of recombinant FVIII) and VWF content of the FVIII product have been also identified as possible risk factors for inhibitor development. 4, 5, 9, [12] [13] [14] The European Medicines Agency (EMA) speculates that the cell origin (human or animal) of rFVIII products could influence immunogenicity, 15 although definitive evidence of an increased inhibitor risk with rFVIII derived from animal cell lines has not been published.
In contrast to PUPs, only around 1% of previously treated patients (PTPs) develop inhibitors. 16 
| MATERIALS AND METHODS

| Patients and study design
| Study drug
Octanate ® is supplied as a freeze-dried concentrate in vials containing 250, 500 or 1000 IU FVIII. The manufacturing process includes 2 validated virus-inactivation steps.
| Clinical outcomes and laboratory parameters
Patients were tested for FVIII inhibitors at baseline, every 3 or 4 EDs until 20 EDs, and thereafter either every 10th ED or every 3 months, whichever came first. Testing was performed at a central laboratory using the Bethesda assay with Nijmegen modification. The cut-off for FVIII inhibitors was ≥0.6 BU. Blood samples were to be taken after a FVIII wash-out period of at least 3 or 4 days, ideally 7 days (especially if the presence of an inhibitor was suspected). FVIII recovery determinations and calculations of incremental in vivo recovery (IVR) were recommended but not mandatory due to blood collection restrictions in babies/toddlers. Where IVR was performed, it was preceded by a wash-out period of at least 48 hours, and a single bolus dose (25-30 IU/kg recommended) was administered. The type of F8 gene mutation was determined for each patient.
The following viral markers were measured at baseline and at 3-month intervals for 5 years, or until 100 EDs were reached: alanine aminotransferase, antibodies to human immunodeficiency virus 1 and 2, hepatitis A virus, hepatitis B virus, hepatitis B surface/antigen, hepatitis B core, hepatitis C virus and parvovirus B19 (including polymerase chain reaction [PCR] testing). Haemostatic efficacy was rated by the investigator (or parent or legal guardian for home-treatment) as "excellent," "good,"
"moderate" or "none." Tolerability was rated by the investigator (or by the parent or legal guardian for home-treatment) as "very good," "good," "satisfactory" or "unsatisfactory." All adverse events (AEs) experienced by patients were analysed based on MedDRA (version 17.1) terminology.
| Statistical analyses and sample size
No sample size calculation was made for this study. The planned sample size of 50 patients complied with the recommended sample size of at least 20 PUPs recommended in the EMA guidelines available at the time of study initiation. 21 The safety population included all patients who received at least one dose of octanate ® . The efficacy population comprised patients who received octanate ® and for whom data were collected post treatment. A surgery subpopulation was analysed separately ( Figure 1 ).
All efficacy analyses were repeated to exclude data after occurrence of the inhibitor from patients who started ITI treatment as increased treatment doses for these patients would bias the assessment of all efficacy parameters.
Statistical analyses were performed using the Statistical Analysis Software (SAS ® ) package (version 9.8, SAS Institute Inc. Cary, North Carolina, USA). Analyses were exploratory only and based upon a type I error probability of 0.05 with confidence interval calculations set at 95%.
| RESULTS
| Patients' baseline characteristics
The safety population comprised 51 Caucasian male patients, all of whom were included in the efficacy population (Table 1) The majority of bleeds (83.0%) were minor, with 15.3% moderate and 1.7% severe. The severity of bleeds by site is shown in Figure 2 .
| Incidence of FVIII inhibitors
FVIII inhibitors were detected in 5 of 51 (9.8%) patients; 4 cases were high-titre inhibitors, 1 was a low-titre inhibitor (Table 2) 
| FVIII recovery
Although IVR determination was optional in this study, 44 of the 51 patients underwent at least one IVR assessment, 36 had a second and one had a third assessment. Notable levels of FVIII were evident in the blood at 15 minutes postinfusion and remained high at 1 hour (Figure 3 ).
Mean (±SD) incremental IVR was 2.0%/IU/kg (±0.7) for the first IVR assessment (n = 44) and 1.9%/IU/kg (±0.5) for the second assessment (n = 36).
| Haemostatic efficacy
Haemostatic efficacy was rated as "excellent" for 99.6%, "good" for 0.3% and "moderate" for 0.02% of all infusions (Table 3 ). The majority of bleeds (95.5%) resolved within 1 or 2 days of treatment (81.2% and 14.3%, respectively). All minor bleeds and the majority of moderate (95.0%) and severe bleeds (76.0%) resolved within 3 days of treatment.
Efficacy for all but one of the 2611 prophylactic infusions was rated as "excellent" (one was rated as "good"), and efficacy for all IVR infusions with available efficacy ratings (n = 80/81) was rated as "excellent."
Twenty-three surgical procedures in 19 patients using octanate Table 4 . There was one case of intracranial haemorrhage, which was treated by craniotomy without further complications.
| Safety and tolerability
A total of 260 treatment-emergent AEs were recorded in 45 (88.2%)
patients. AEs reported were typical for any paediatric or haemophilia F I G U R E 3 Factor VIII concentrations (%) for first and second determinations on a semilogarithmic scale. Geometric means and 95% confidence interval for the efficacy population* (N = 51). Values below limit of quantification were set to zero and are not included in the geometric mean. *Excluding data following inhibitor occurrence in patients who received immune tolerance induction treatment The tolerability of octanate ® was considered "very good" in the vast majority of the 8674 infusions (99.98%) and 2 (0.02%) were assessed as "good".
| DISCUSSION AND CONCLUSIONS
The immunogenicity and efficacy of octanate ® were investigated in paediatric PUPs, and a low rate of inhibitor development was observed.
In the 51 PUPs in this study, 5 (9.8%) patients developed inhibitors, 4 who reached ≥20 EDs (or developed an inhibitor <20 EDs) and had FVIII:C <1% at baseline, the incidence of inhibitor development was 11.1%. This inhibitor incidence compares very favourably with historical reports of incidences of up to 45% in similar populations. 4, 5, 22 The influence of FVIII product type on inhibitor incidence has been intensely debated over the past decade. Some studies and metaanalyses have reported an increased inhibitor risk with rFVIII compared with pdFVIII, 5, [23] [24] [25] [26] [27] whereas other studies and meta-analyses reported no difference in inhibitor risk. 4, 7, 12, 28, 29 In a retrospective study of 99
PUPs, no inhibitors were detected in 11 PUPs treated with wilate ® , a pdFVIII concentrate containing FVIII and VWF in a physiological 1:1 ratio, and inhibitors were detected in 38% of PUPs treated with rFVIII concentrates derived from hamster cell lines. 5 Comparisons of inhibitor risk have been limited by the heterogeneity of study designs and patient populations. For example, the EPIC study attempted to confirm a reported inhibitor incidence of only 4%
reported by Kurnik et al 30 with a weekly prophylaxis regimen and in fact found inhibitor development in 42% of patients. 31 The small cohort size of studies reporting inhibitor development likely contributes to discrepancies and must be taken into account when attempting to make direct comparisons. A meta-analysis attempted to overcome some of these limitations by analysing data in 761 PUPs with severe or moderate haemophilia. 9 Unadjusted inhibitor rates were higher in patients treated with rFVIII compared with patients treated with pd-FVIII (40% vs 22%); however, this difference did not persist after adjustment for confounding factors. More recently, the results of the first randomized controlled study to investigate the impact of FVIII types on inhibitor incidence were published. The SIPPET study compared inhibitor rates in PUPs treated with pdFVIII (n = 125) or hamster cell line-derived rFVIII (n = 126 The associations did not change substantially after adjustment for putative confounders. 6 It is important to note the large variation between the inhibitor rate reported in patients treated with pdFVIII in the SIPPET study (26.8%) and the rate reported in this study (11.1%) may be related to differences in patient populations studied. For example, the majority of patients enrolled in the SIPPET study were from Egypt, India and Iran, whereas patients enrolled in this study were exclusively Caucasian.
Mouse studies have demonstrated higher levels of FVIII inhibitors following administration of hamster cell-derived rFVIII products compared with pdFVIII, and pre-incubation of rFVIII with VWF has been shown to reduce rFVIII immunogenicity. This suggests that an underlying cause of product-related development of a FVIII immune response may lie in the VWF-binding affinity and the presence of antigenic epitopes in animal cell-derived rFVIII products. 17, 32 A number of reports have suggested that the use of on-demand treatment is associated with a higher risk of inhibitor development than regular prophylaxis. 33 In this study, all 5 patients who developed inhibitors received on-demand treatment. Furthermore, a high intensity of FVIII exposure (≥150 IU/kg/wk) is considered a strong risk factor for inhibitor development in PUPs, especially during surgical coverage. 9 In this study, 2 patients developed transient inhibitors during surgery. Reported inhibitor rates may vary depending on the frequency of testing; in this study, patients were tested frequently for FVIII inhibitor development. 34 Certain mutation types, such as intron 22 inversions, have been associated with a substantially higher risk of inhibitor development. 35 Intron 22 inversions were observed in 52.9% (27/51) of patients in this study. Two of these 27 patients (7.4%) developed clinically relevant FVIII inhibitors. T A B L E 4 Description, total dose and outcome of major surgical procedures
In this study, the mean incremental IVR of octanate ® of 2.0%/IU/ kg (±0.7) for the first assessment (n = 44) and 1.9%/IU/kg (±0.5) for the second assessment (n = 36) are slightly lower than the 2.4%/IU/kg observed for octanate ® in adults, which is consistent with an expected lower IVR for children compared with adults. 36 The values are consistent with values reported for other FVIII concentrates in previously treated paediatric patients. [37] [38] [39] [40] The haemostatic efficacy of octanate ® was rated in the study as Early and efficient prophylaxis is key to successful long-term management of patients with HA. 13 The data reported here demonstrate that octanate ® is associated with a low rate of inhibitor development in PUPs, including those undergoing surgical procedures. The data are consistent with previous findings in PTPs demonstrating that octanate ® is an efficacious and well-tolerated human FVIII for the management of patients with HA.
